GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WuXi Biologics (Cayman) Inc (FRA:1FW2) » Definitions » Total Inventories

WuXi Biologics (Cayman) (FRA:1FW2) Total Inventories : €227 Mil (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is WuXi Biologics (Cayman) Total Inventories?

WuXi Biologics (Cayman)'s total inventories for the quarter that ended in Dec. 2023 was €227 Mil. WuXi Biologics (Cayman)'s average total inventories from the quarter that ended in Jun. 2023 to the quarter that ended in Dec. 2023 was €240 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. WuXi Biologics (Cayman)'s Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was €0.00.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. WuXi Biologics (Cayman)'s Days Inventory for the six months ended in Dec. 2023 was 64.66.

Inventory Turnover measures how fast the company turns over its inventory within a year. WuXi Biologics (Cayman)'s Inventory Turnover for the quarter that ended in Dec. 2023 was 2.82.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. WuXi Biologics (Cayman)'s Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.22.


WuXi Biologics (Cayman) Total Inventories Historical Data

The historical data trend for WuXi Biologics (Cayman)'s Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi Biologics (Cayman) Total Inventories Chart

WuXi Biologics (Cayman) Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Inventories
Get a 7-Day Free Trial Premium Member Only Premium Member Only 51.25 136.29 234.46 308.85 226.77

WuXi Biologics (Cayman) Semi-Annual Data
Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 234.46 302.90 308.85 253.28 226.77

WuXi Biologics (Cayman) Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


WuXi Biologics (Cayman)  (FRA:1FW2) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

WuXi Biologics (Cayman)'s Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is

Net-Net Working Capital Per Share (Q: Dec. 2023 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(1443.97+0.75 * 726.083+0.5 * 226.771-1612.776
-0-473.421)/4257.5
=0.00

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

WuXi Biologics (Cayman)'s Days Inventory for the six months ended in Dec. 2023 is calculated as:

Days Inventory=Average Total Inventories (Q: Dec. 2023 )/Cost of Goods Sold (Q: Dec. 2023 )*Days in Period
=240.024/677.449*365 / 2
=64.66

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

WuXi Biologics (Cayman)'s Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Dec. 2023 ) / Average Total Inventories (Q: Dec. 2023 )
=677.449 / 240.024
=2.82

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

WuXi Biologics (Cayman)'s Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=240.024 / 1097.057
=0.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


WuXi Biologics (Cayman) Total Inventories Related Terms

Thank you for viewing the detailed overview of WuXi Biologics (Cayman)'s Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


WuXi Biologics (Cayman) (FRA:1FW2) Business Description

Address
No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092
WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 15 billion. North American represented 55.6% of total revenue in 2022. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual-sourcing strategy by providing drug products and large-scale drug substance manufacturing.

WuXi Biologics (Cayman) (FRA:1FW2) Headlines

No Headlines